Log In
Print
BCIQ
Print
Print this Print this
 

IGN523

  Manage Alerts
Collapse Summary General Information
Company Igenica Inc.
DescriptionHuman mAb targeting solute carrier family 3 member 2 (SLC3A2; CD98)
Molecular Target Solute carrier family 3 member 2 (SLC3A2) (CD98)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I
Standard IndicationAcute myelogenous leukemia (AML)
Indication DetailsTreat acute myelogenous leukemia (AML)
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today